Have Insiders Sold Pediatrix Medical Group Shares Recently?
Have Insiders Sold Pediatrix Medical Group Shares Recently?
We'd be surprised if Pediatrix Medical Group, Inc. (NYSE:MD) shareholders haven't noticed that the Chair, Mark Ordan, recently sold US$424k worth of stock at US$15.35 per share. That sale was 17% of their holding, so it does make us raise an eyebrow.
如果Pediatrix Medical Group, Inc.(紐約證券交易所代碼:MD)的股東沒有注意到董事長馬克·奧爾丹最近以每股15.35美元的價格出售了價值42.4萬美元的股票,我們會感到驚訝。那次出售佔他們持股量的17%,因此確實讓我們大吃一驚。
The Last 12 Months Of Insider Transactions At Pediatrix Medical Group
Pediatrix Medical Group 過去 12 個月的內幕交易
Over the last year, we can see that the biggest insider sale was by the insider, C. Richards, for US$504k worth of shares, at about US$10.08 per share. So it's clear an insider wanted to take some cash off the table, even below the current price of US$14.15. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. We note that the biggest single sale was only 22% of C. Richards's holding.
在過去的一年中,我們可以看到,最大的內幕出售是知情人C. Richards,出售了價值50.4萬美元的股票,每股約10.08美元。因此,很明顯,一位內部人士想從桌上拿出一些現金,甚至低於目前的14.15美元。通常,當內部人士以低於當前價格的價格出售時,我們認爲這令人沮喪,因爲這表明他們對較低的估值感到滿意。儘管內幕拋售不是一個積極的信號,但我們無法確定這是否意味着內部人士認爲股票已完全估值,因此這只是一個弱勢信號。我們注意到,最大的單筆銷售僅佔C. Richards持股量的22%。
Pediatrix Medical Group insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
去年,Pediatrix Medical Group內部人士沒有購買任何股票。您可以看到下圖所示的去年的內幕交易(公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
如果你像我一樣,那麼你一定不想錯過這份免費的小盤股清單,這些股票不僅被內部人士買入,而且估值也很有吸引力。
Insider Ownership
內部所有權
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 1.6% of Pediatrix Medical Group shares, worth about US$19m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
許多投資者喜歡查看公司內部人士擁有多少股份。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。業內人士擁有Pediatrix Medical Group1.6%的股份,價值約1900萬美元。這種內部所有權水平不錯,但還沒有特別突出。這無疑表明了一定程度的一致性。
So What Does This Data Suggest About Pediatrix Medical Group Insiders?
那麼,這些數據對Pediatrix Medical Group內部人士有什麼啓示呢?
Insiders sold Pediatrix Medical Group shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. Insiders own shares, but we're still pretty cautious, given the history of sales. We're in no rush to buy! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. While conducting our analysis, we found that Pediatrix Medical Group has 3 warning signs and it would be unwise to ignore them.
業內人士最近出售了Pediatrix Medical Group的股票,但他們沒有購買任何股票。在過去的一年裏,沒有任何能讓我們感到安慰的購買。內部人士擁有股票,但考慮到銷售歷史,我們仍然相當謹慎。我們並不急於購買!因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解這家公司面臨的風險。在進行分析時,我們發現Pediatrix Medical Group有3個警告信號,忽視它們是不明智的。
Of course Pediatrix Medical Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,Pediatrix醫療集團可能不是最好的買入股票。因此,您可能希望看到這個免費的高質量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?擔心內容嗎?直接聯繫我們。或者,發送電子郵件給編輯組(網址爲)simplywallst.com。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。